8-K: Avalon GloboCare and Qi Diagnostics Partner to Develop Cannabis Breathalyzer for Impaired Driving Detection

Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics Limited to co-develop a volatile organic compound (VOC) nanosensor-based cannabis breathalyzer aimed at real-time detection of impaired driving.

Summary

• Avalon GloboCare Corp., through its wholly-owned subsidiary Q&A Distribution, LLC, has signed a definitive agreement with Qi Diagnostics Limited for the co-development of a VOC nanosensor-based breathalyzer to detect 9-tetrahydrocannabinol (THC).
• The project is structured around four key milestones: (1) data collection, software development, and prototype design drafting (4 months); (2) completion of prototype design and component sourcing (3 months); (3) prototype production, beta-testing, and intellectual property filings (4 months); and (4) human testing, clinical validation, and United States FDA registration (6 months).
• Q&A Distribution, LLC will make milestone-based payments to Qi Diagnostics totaling $1,000,000 over the course of the project.
• The payment schedule includes: $120,000 for Milestone 1 (including $25,000 upfront from MOU), $180,000 for Milestone 2, $300,000 for Milestone 3, and $400,000 for Milestone 4.
• Qi Diagnostics will retain control over the intellectual property (IP) developed under the agreement, while Q&A will accrue a passive financial interest in the IP, reaching 50% upon completion of all milestones and payments.
• Expenses for trademark, IP, CE Mark filings (Milestone 3) and United States FDA registration (Milestone 4) will be equally shared by Q&A and Qi Diagnostics, and are excluded from the milestone payments.
• The parties plan to jointly publish research papers, present at conferences, and file patent applications related to the project.
• During the fourth milestone, Qi Diagnostics and Q&A will negotiate to form a USA-based Joint Venture to handle US regulatory and commercial operations for the device.

Sentiment

Score: 7

Explanation: The agreement represents a positive strategic move into a relevant and growing market, leveraging existing partnerships and technology. However, the early stage of development, significant financial commitment, and the passive nature of Avalon's IP interest introduce notable risks and future negotiation requirements.

Positives

• The strategic collaboration leverages Avalon's regulatory expertise and Qi Diagnostics' VOC nanosensor technology to address a growing market need for cannabis detection.
• The development of a real-time, non-invasive cannabis breathalyzer has the potential to significantly enhance public safety by aiding law enforcement and workplace safety.
• The project has a clear, milestone-based development plan with defined timelines and payment structures, providing a structured approach to product development.
• Avalon already markets the KetoAir breathalyzer from Qi Diagnostics, indicating a pre-existing relationship and familiarity with the partner's technology.
• The agreement includes provisions for joint publication of research and patent filings, which can enhance the companies' scientific and intellectual property portfolios.

Negatives

• Q&A's ownership in the intellectual property is limited to a passive financial interest, with Qi Diagnostics retaining control over the IP, including protection, licensing, enforcement, and commercialization.
• The total financial commitment from Q&A is $1,000,000, which is a significant investment for an R&D project with inherent uncertainties.
• Funding and execution for regulatory compliance (e.g., FDA registration) are explicitly excluded from the milestone payments and require further negotiation between the parties, potentially leading to additional costs or delays.
• The R&D process is acknowledged to be inherently uncertain and subject to delays or modifications due to unforeseen technical, regulatory, or operational challenges.

Risks

• The Research and Development (R&D) process is inherently uncertain and may be subject to delays or modifications due to unforeseen technical, regulatory, or operational challenges.
• Regulatory compliance funding and execution are not covered by the current agreement and require further negotiation, posing a risk of additional costs or failure to secure necessary approvals.
• Q&A's passive financial interest in the Intellectual Property means it does not have direct control over the IP's protection, licensing, enforcement, or commercialization, which could limit its strategic flexibility.
• There is a risk that the co-developed device may not achieve the desired performance or regulatory approval, impacting its commercial viability.
• The success of the project relies heavily on the continued collaboration and good faith negotiations between the parties, particularly for the formation of a US-based Joint Venture and regulatory funding.

Future Outlook

The company aims to provide a real-time, non-invasive cannabis detection solution to support law enforcement and workplace safety. Clinical testing and validation will occur in cannabis-legalized jurisdictions within the United States, with potential expansion to Canada, the U.K., and the European Union. During the final development phase, Avalon and Qi Diagnostics plan to negotiate the formation of a USA-based Joint Venture to manage US regulatory and commercial operations for the device.

Management Comments

• "By combining Avalons regulatory expertise with Qi Diagnostics VOC nanosensor technology, we aim to provide a real-time, non-invasive cannabis detection solution that can support law enforcement and workplace safety." David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.

Industry Context

The co-development of a cannabis breathalyzer addresses a growing need for rapid and reliable detection of cannabis impairment, particularly relevant in jurisdictions where cannabis has been legalized. This initiative positions Avalon GloboCare to enter the expanding market for point-of-care diagnostic devices for substance detection, building on its existing relationship with Qi Diagnostics through the marketing of the KetoAir breathalyzer. The focus on real-time detection for impaired driving and workplace safety aligns with increasing public and regulatory concerns.

Related Party Transactions

• The definitive agreement is between Avalon GloboCare Corp., its wholly-owned subsidiary Q&A Distribution, LLC, and Qi Diagnostics Limited.

Stakeholder Impact

• Shareholders: Potential for future revenue streams from a new product in a growing market, but also exposure to significant R&D costs and inherent development risks.
• Employees: Potential for increased R&D and commercialization activities, possibly leading to new roles or expanded teams.
• Customers (future): Law enforcement agencies, employers, and potentially the general public will benefit from a new tool for cannabis detection and impairment assessment.
• Suppliers: Qi Diagnostics Limited is a key partner and recipient of significant development funds.
• Creditors: The $1,000,000 financial commitment represents a notable allocation of capital.

Next Steps

• Completion of Milestone 1: THC Nano-sensor testing, data collection and analysis, software development, research-grade validation, drafting of prototype design (within 4 months).
• Completion of Milestone 2: Prototype design and sourcing of components (within 3 months after Milestone 1).
• Completion of Milestone 3: Prototype production, calibration, beta-testing, and filing for trademark, USPTO/PCT patents, and CE Mark (within 4 months after Milestone 2).
• Completion of Milestone 4: Human testing, clinical data collection and validation, and filing for United States FDA registration (within 6 months after Milestone 3).
• Negotiation and formation of a USA-based Joint Venture during Milestone 4 to assume US regulatory and commercial operations.
• Potential extension of regulatory pathway and approval process to Canada, U.K., and European Union.

Key Dates

Recommendation

Keywords

Cannabis breathalyzer, THC detection, VOC nanosensor, Point-of-care diagnostics, Impaired driving, Medical device development, Co-development agreement, Intellectual property, Avalon GloboCare, Qi Diagnostics, Regulatory approval, FDA registration